Navigation Links
Leading Experts Endorse Bioheart's Muscle Stem Cell MyoCell Therapy
Date:7/7/2009

"would", "estimate", or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.

Investors and others are cautioned that a variety of factors, including certain risks, may affect our business and cause actual results to differ materially from those set forth in the forward-looking statements. These risk factors include, without limitation, (i) our ability to obtain additional financing; (ii) our ability to control and reduce our expenses; (iii) our ability to establish a distribution network for and commence distribution of certain products for which we have acquired distribution rights; (iv) our ability to timely and successfully complete our clinical trials; (v) the occurrence of any unacceptable side effects during or after preclinical and clinical testing of our product candidates; (vi) the timing of and our ability to obtain and maintain regulatory approvals for our product candidates; (vii) our dependence on the success of our lead product candidate; (viii) our inability to predict the extent of our future losses or if or when we will become profitable; (ix) our ability to protect our intellectual property rights; and (x) intense competition. The Company is also subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2008, as amended by its Annual Report on Form 10-K/A, and its Quarterly Reports on Form 10-Q for the quarters ended March 31, 2008; June 30, 2008 and September 30, 2008.

    Contact:
    At the Company:
    Howard J. Leonhardt, Chief Executive Officer
    (954) 835-1500


'/>"/>
SOURCE Bioheart, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Afinitor(R) Phase II Data Show Positive Results for Patients With Multiple Types of Lymphoma, Leading to Phase III Trial
2. New Report Shows Record Number of Medicines in Development to Treat Leading Causes of Cancer
3. Abbotts Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years
4. Dr. James F. Pingpank to Present at Leading Regional Therapies Conference
5. RAD001 Shows Potential to Reverse Resistance to Herceptin(R)* in Metastatic Breast Cancer Patients, Leading to Phase III Trial
6. PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru
7. Durezol(TM) in the Treatment of Uveitis and Ganciclovir in the Treatment of Herpetic Keratitis: Studies of Treatments for Leading Causes of Blindness to Be Presented
8. Nuvo Research presents positive Phase III study results for Pennsaid at leading rheumatology conference
9. News Media Advisory: Worlds Leading Surgical Oncologists to Gather at McLaren Regional Medical Center to Present Latest Work on Breast, Gastrointestinal Cancer Treatments
10. Bioheart Announces 35 Leading U.S. Heart Failure Centers Engaged in Phase II/III Marvel Trial of Myogenic Cells for Treating Advanced Heart Failure
11. Leading Cardiologist Joins Ontario Research Firm to Conduct New Clinical Trial on the Effect of Pantethine on Cholesterol Levels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... Aug. 22, 2014  Landauer, Inc. (NYSE: ... radiation measurement and monitoring, outsourced medical physics services and ... William E. Saxelby , its President and Chief Executive ... Executive Officer and as a member of the Board ... will be replaced on an interim basis by ...
(Date:8/21/2014)... AUSTIN, Texas , Aug. 21, 2014  Vermillion, ... company focused on gynecologic cancers and women,s health, has ... of Sales and Managed Markets. Ms. Bauzon ... traction and expanding payer coverage for laboratory services companies. ... most recently with PerkinElmer, Inc., where she held the ...
(Date:8/21/2014)... Aug. 21, 2014 /CNW/ - Eisai Limited is pleased to ... the first-of-its-kind comic book available in Canada ... designed specifically to educate children and their parents about epilepsy, ... affecting more than 300,000 Canadians. Eisai is guided by ... , in which the patient is central – there was ...
Breaking Medicine Technology:Landauer, Inc. Announces Executive Management Change 2Vermillion Appoints Holly B. Bauzon as VP of Sales and Managed Markets 2Eisai Pleased to Support Canadian Epilepsy Alliance Comic Book that Teaches Children About Epilepsy 2
... INDIANAPOLIS, Nov. 2, 2010 Eli Lilly and Company (NYSE: ... focused on diabetes in China, where the incidence of the disease ... in Shanghai in the second half of 2011, will focus on ... leadership in this disease area and the priority Lilly places on ...
... Back Awards is now accepting nominations to honor individuals ... The Welcome Back Awards , now in its 13th ... to recognize outstanding achievements in the fight against depression and ... Welcome Back Awards continue to motivate healthcare providers ...
Cached Medicine Technology:Eli Lilly and Company to Open a Diabetes-Focused Research Center in China 2Eli Lilly and Company to Open a Diabetes-Focused Research Center in China 3Eli Lilly and Company to Open a Diabetes-Focused Research Center in China 4The Welcome Back Awards Seeks Nominations to Honor Leaders in the Depression Community 2The Welcome Back Awards Seeks Nominations to Honor Leaders in the Depression Community 3
(Date:8/22/2014)... somatic mutation at amino acid 918 in the RET ... cell lung cancer (SCLC) tumors and enforced expression of ... signaling and cell growth. , SCLC is a highly ... lung cancers and is strongly associated with tobacco smoking. ... examined for genomic alterations and targeted therapies are approved ...
(Date:8/22/2014)... 22, 2014 Paying tuition and other ... the coming year for four nurse educators pursuing advanced ... League for Nursing Foundation for Nursing Education . This ... $28,000, $10,000 more than in 2013, thanks to these ... and Elizabeth Isaac Marcil Endowment Funds, both donated by ...
(Date:8/22/2014)... 22, 2014 Testosterone treatment lawsuits ... U.S. courts on behalf of men who allegedly ... of prescription low testosterone therapies, Bernstein Liebhard LLP ... was filed against Pfizer Inc. on July 31st ... heart issues due to his use of Depo-Testosterone. ...
(Date:8/22/2014)... CarePoint Health is proud to ... Geriatrics, Hospice and Palliative Care, Dr. Michelle Reisner, ... Their system welcomes Dr. Reisner to the community. ... CarePoint Health Medical Group, a comprehensive network of ... a wide range of specialties. This latest acquisition ...
(Date:8/22/2014)... -- Back-to-school time provides an opportunity for parents to ... schedules, an expert suggests. "Forget New Year,s resolutions; ... be the start of a new fitness and exercise ... at the University of the Sciences in Philadelphia, said ... activities likely to build up, "it,s important for mom ...
Breaking Medicine News(10 mins):Health News:Novel oncogenic RET mutation found in small cell lung cancer 2Health News:NLN Foundation for Nursing Education Announces 2014 Faculty Scholarship Awards 2Health News:NLN Foundation for Nursing Education Announces 2014 Faculty Scholarship Awards 3Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 2Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 3Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 4Health News:Dr. Reisner Joins CarePoint Health Medical Group 2Health News:With Kids in School, Parents Can Work Out 2
... Promote Patient Safety for Care Abroad, CHICAGO, ... considering traveling abroad for medical care, new guiding,principles ... American Medical,Association,s (AMA) annual policy-making meeting. The nine ... care abroad for consideration,by patients, employers, insurers and ...
... and ,lack of time, as, the top three factors that ... ... 17 Findings from a survey,released today reveal that the vast ... less than half of those who,consider making lifestyle changes (46%) are ...
... Functioning in Fibromyalgia Patients, INDIANAPOLIS, June ... (FDA) has approved Cymbalta(R) (duloxetine HCl) for ... disorder, Eli Lilly,and Company (NYSE: LLY ... serotonin-,norepinephrine reuptake inhibitor with proven efficacy for ...
... FRANCISCO, June 16 Following a study,indicating that strong ... community, Asian & Pacific Islander Wellness Center has,developed a ... of,stigma in the Chinese community., Joan Chen generously ... for the TalkAIDS campaign, where she asks "Don,t think ...
... 16 The Concerned Shareholders of Biovail,Corporation (NYSE: BVF ... of Biovail Corporation:, , June 16, 2008, William ... Mississauga Road Mississauga, Ontario l5N 8M5, Dear Mr. ... debate between the two of,us either Wednesday or Thursday of ...
... Product Line and International ... ... the leader,in legal holds and retention management solutions, announced it secured ... Lightspeed Venture Partners, Azure Capital, Granite,Ventures, and Cipio Partners, all renewed ...
Cached Medicine News:Health News:AMA Provides First Ever Guidance on Medical Tourism 2Health News:LIVESTRONG.COM Survey Reveals 86 Percent of Americans Attempt Changes to Improve Their Health but Less Than Half are Successful 2Health News:LIVESTRONG.COM Survey Reveals 86 Percent of Americans Attempt Changes to Improve Their Health but Less Than Half are Successful 3Health News:LIVESTRONG.COM Survey Reveals 86 Percent of Americans Attempt Changes to Improve Their Health but Less Than Half are Successful 4Health News:FDA Approves Cymbalta(R) for the Management of Fibromyalgia 2Health News:FDA Approves Cymbalta(R) for the Management of Fibromyalgia 3Health News:FDA Approves Cymbalta(R) for the Management of Fibromyalgia 4Health News:FDA Approves Cymbalta(R) for the Management of Fibromyalgia 5Health News:FDA Approves Cymbalta(R) for the Management of Fibromyalgia 6Health News:TalkAIDS: A&PI Wellness Center Launches a New Anti-Stigma Campaign With International Star Joan Chen 2Health News:Letter Challenges Biovail CEO to a Debate 2Health News:Letter Challenges Biovail CEO to a Debate 3Health News:PSS Systems Secures $18 Million in Financing 2Health News:PSS Systems Secures $18 Million in Financing 3Health News:PSS Systems Secures $18 Million in Financing 4
... stabilized hyaluronic acid-based dermal filler and ... the U.S. market. It is indicated ... facial wrinkles and folds (such as ... under the skins surface to replenish ...
... Response is a whole blood ... be used at the point-of-care. ... screen and data management features, ... options. QC and operator lockout ...
... clinically proven aminophylline directly to the area ... reduction with the aminophylline containing cream has ... increase in the firmness of the thighs. ... skin where it causes the body fat ...
... is a unique, non-invasive way of ... of cellulite and improving overall skin ... was used to rehabilitate scars, burns ... surprising side-affect was discovered - the ...
Medicine Products: